Drug Profile

ATL 201

Alternative Names: Astatine-211-J591; Astatine-211-labelled-anti-PSMA monoclonal antibody J591

Latest Information Update: 03 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ATLAB Pharma
Developer Telix Pharmaceuticals
Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

03 Oct 2023 Discontinued - Preclinical for Prostate cancer in France (Parenteral) (Telix Pharmaceuticals pipeline, October 2023)
28 Feb 2021 No recent reports of development identified for preclinical development in Prostate-cancer in France (Parenteral)
10 Sep 2018 ATLAB Pharma has been acquired by Telix Pharmaceuticals

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com